Revenue Increases 26% to a Record $22.0 Million, Generating GAAP EPS of $0.24 BOCA RATON, Fla., May 07, 2025 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended March 31, 2025. “We are extremely pleased to report another record-setting quarter, marking
Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company’s pipeline addressing multiple sizable markets Interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on
TORONTO, May 07, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders, which was held via live webcast on Wednesday, May 7, 2025. A total of 132,500,374 common shares were voted at the meeting, representing
Headlines Revenue of $78M; free cash flow of $13.1M marks fourth consecutive positive quarter Company reiterates full-year guidance for revenue and raises full-year guidance for profitability and cash flow Continued innovation and customer momentum for Cerence xUI, the company’s next-gen platform BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”),
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is
– Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025 Expect data readouts for DISC-0974 program in H2 2025, including
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra
XIAMEN, China, May 02, 2025 (GLOBE NEWSWIRE) — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT) today released its audited financial results for the fiscal year ended December 31, 2024. Under the strategic guidance of management, the company actively seized opportunities in the gold industry, completing the strategic procurement of 1
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are